Branded Legacy, Inc. Aims to Transform Opioid Overdose Treatment
Branded Legacy, Inc. (OTC: BLEG), a dynamic company dedicated to advancing life sciences and wellness innovation, is making significant strides in tackling the opioid crisis with its newest development—an intranasal naloxone spray. This innovative product is currently being prepared for FDA approval through a Pre-Abbreviated New Drug Application (Pre-ANDA) briefing package by its subsidiary BioLegacy Evaluative Group, marking a crucial step in the company's regulatory strategy.
Pioneering a Transformative Delivery Method
The introduction of the intranasal naloxone device is crucial not only for its potential to save lives but also for its design that adheres to a Target Product Profile (TPP). This profile outlines a 2 mg and 4 mg naloxone HCl nasal spray specifically aimed at addressing acute opioid overdoses, featuring a shelf life of 18–36 months. These capabilities ensure that the product is viable and accessible when needed most.
Understanding the Pre-ANDA Briefing Package
The detailed FDA briefing package being assembled includes several vital components:
- CMC Program: This encompasses the necessary Chemistry, Manufacturing, and Controls specifications that conform with ICH guidelines, ensuring both the drug substance and the device's quality are up to standard.
- PK Study Protocol: A critical crossover bioequivalence study involving 60 subjects will assess the pharmacokinetic parameters against Narcan® to gauge effectiveness.
- Device & Human Factors Study: This will involve usability tests with participants, aimed at ensuring easy accessibility for emergency use situations.
Strategic Guidance from the FDA
To progress with its application, BioLegacy aims to obtain specific guidance from the FDA:
- Confirming that a single pivotal pharmacokinetic study meets bioequivalence criteria.
- Understanding expectations for validating its unique device's human factors.
- Clarifying requirements related to extractables and leachables testing for the materials used.
Commitment to Accessibility and Affordability
Kristian Thorlund, the Executive Chair of Branded Legacy, underscores the company’s dedication to providing affordable overdose-reversal treatments. He emphasizes the goal of making effective solutions like naloxone accessible for communities grappling with opioid challenges. The company aims to replicate the efficacy of Narcan® while significantly lowering production costs, which could enhance global availability.
Technological Foundations and Future Directions
This air-driven delivery system is foundational to BioLegacy’s growing portfolio and reflects the company's commitment to innovative drug delivery solutions. The advanced manufacturing facility the company operates further supports rapid formulation development and robust regulatory processes, accelerating the trajectory toward market readiness.
About BioLegacy Evaluative Group, Inc.
BioLegacy Evaluative Group, Inc. is dedicated to pioneering innovative therapies tackling urgent health issues worldwide. Collaboration with leading institutions, such as McMaster University and Stanford University, enhances their capabilities, fostering solutions that are both effective and scalable.
About Branded Legacy, Inc.
Branded Legacy, Inc. (OTC: BLEG) focuses on developing solutions for addiction treatment and harm reduction through its strategic partnerships and state-of-the-art production facilities. This innovative approach positions the company to lead in addressing pivotal public health challenges through effective product development.
Investor Relations:
Branded Legacy, Inc.
Email: info@brandedlegacy.com
Phone: 877-250-9077
Frequently Asked Questions
What is the main focus of Branded Legacy, Inc.?
Branded Legacy, Inc. primarily focuses on life sciences and wellness innovation, particularly in developing solutions for addiction treatment and overdose interventions.
What is the purpose of the FDA Pre-ANDA briefing package?
The Pre-ANDA briefing package is designed to prepare Branded Legacy’s intranasal naloxone spray for FDA approval, facilitating the regulatory pathway for the product’s commercial launch.
How does the intranasal naloxone spray work?
This product delivers naloxone through the nasal cavity, providing a quick and effective response to opioid overdose, potentially saving lives during emergency situations.
What partnerships support Branded Legacy's initiatives?
Branded Legacy collaborates with notable institutions like McMaster University and Stanford University to enhance research and development capabilities for their innovative solutions.
How does Branded Legacy ensure product quality?
The company adheres to stringent Chemistry, Manufacturing, and Controls (CMC) guidelines, ensuring high-quality production standards in line with regulatory requirements.
